Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 797

1.

Validation of Mayo Clinic Staging System for Light Chain Amyloidosis With High-Sensitivity Troponin.

Kumar SK, Gertz MA, Dispenzieri A.

J Clin Oncol. 2018 Nov 15:JCO1801398. doi: 10.1200/JCO.18.01398. [Epub ahead of print] No abstract available.

PMID:
30433848
2.

Venetoclax for the treatment of multiple myeloma.

Vaxman I, Sidiqi H, Gertz M.

Expert Rev Hematol. 2018 Nov 14. doi: 10.1080/17474086.2018.1548931. [Epub ahead of print]

PMID:
30428277
3.

Bortezomib, lenalidomide, and dexamethasone (VRd) followed by autologous stem cell transplant for multiple myeloma.

Sidiqi MH, Aljama MA, Bin Riaz I, Dispenzieri A, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA.

Blood Cancer J. 2018 Nov 8;8(11):106. doi: 10.1038/s41408-018-0147-7.

4.

Safety and efficacy of propylene glycol-free melphalan as conditioning in patients with AL amyloidosis undergoing stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Wolf RC, Kumar SK, Gertz MA.

Bone Marrow Transplant. 2018 Nov 2. doi: 10.1038/s41409-018-0388-x. [Epub ahead of print]

PMID:
30390060
5.

Systemic immunoglobulin light chain amyloidosis.

Merlini G, Dispenzieri A, Sanchorawala V, Schönland SO, Palladini G, Hawkins PN, Gertz MA.

Nat Rev Dis Primers. 2018 Oct 25;4(1):38. doi: 10.1038/s41572-018-0034-3. Review.

PMID:
30361521
6.

Waldenström macroglobulinemia: 2018 update on diagnosis, risk stratification, and management.

Gertz MA.

Am J Hematol. 2018 Oct 17. doi: 10.1002/ajh.25292. [Epub ahead of print]

PMID:
30328142
7.

Relapse after complete response in newly diagnosed multiple myeloma: implications of duration of response and patterns of relapse.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Leukemia. 2018 Oct 15. doi: 10.1038/s41375-018-0271-1. [Epub ahead of print]

PMID:
30323358
8.

Primary systemic amyloidosis in patients with Waldenström macroglobulinemia.

Zanwar S, Abeykoon JP, Ansell SM, Gertz MA, Dispenzieri A, Muchtar E, Sidana S, Tandon N, Rajkumar SV, Dingli D, Go R, Lacy MQ, Kourelis T, Witzig TE, Inwards D, Buadi F, Gonsalves W, Habermann T, Johnston P, Nowakowski G, Kyle RA, Kumar S, Kapoor P.

Leukemia. 2018 Oct 12. doi: 10.1038/s41375-018-0286-7. [Epub ahead of print] No abstract available.

PMID:
30315235
9.

Daratumumab-based therapy in patients with heavily-pretreated AL amyloidosis.

Abeykoon JP, Zanwar S, Dispenzieri A, Gertz MA, Leung N, Kourelis T, Gonsalves W, Muchtar E, Dingli D, Lacy MQ, Hayman SR, Buadi F, Warsame R, Kyle RA, Rajkumar V, Kumar S, Kapoor P.

Leukemia. 2018 Sep 28. doi: 10.1038/s41375-018-0262-2. [Epub ahead of print] No abstract available.

PMID:
30267007
10.

Optimizing deep response assessment for AL amyloidosis using involved free light chain level at end of therapy: failure of the serum free light chain ratio.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Gonsalves W, Kourelis TV, Warsame R, Russell SJ, Lust JA, Lin Y, Go RS, Zeldenrust SR, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2018 Sep 26. doi: 10.1038/s41375-018-0258-y. [Epub ahead of print] No abstract available.

PMID:
30258095
11.

Utility and prognostic value of 18 F-FDG positron emission tomography-computed tomography scans in patients with newly diagnosed multiple myeloma.

Aljama MA, Sidiqi MH, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Dingli D, Muchtar E, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Warsame RM, Kourelis T, Hwa YL, Kapoor P, Kyle RA, Leung N, Go RS, Rajkumar SV, Kumar SK.

Am J Hematol. 2018 Dec;93(12):1518-1523. doi: 10.1002/ajh.25279. Epub 2018 Oct 2.

PMID:
30194770
12.

Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial.

Waddington-Cruz M, Ackermann EJ, Polydefkis M, Heitner SB, Dyck PJ, Barroso FA, Wang AK, Berk JL, Dyck PJB, Monia BP, Hughes SG, Tai L, Jesse Kwoh T, Jung SW, Coelho T, Benson MD, Gertz MA.

Amyloid. 2018 Aug 31:1-9. doi: 10.1080/13506129.2018.1503593. [Epub ahead of print]

PMID:
30169969
13.

The clinical implication of monoclonal gammopathies: monoclonal gammopathy of undetermined significance and monoclonal gammopathy of renal significance.

Batko K, Malyszko J, Jurczyszyn A, Vesole DH, Gertz MA, Leleu X, Suska A, Krzanowski M, Sulowicz W, Malyszko JS, Krzanowska K.

Nephrol Dial Transplant. 2018 Aug 28. doi: 10.1093/ndt/gfy259. [Epub ahead of print]

PMID:
30169860
14.

Predictors of symptomatic hyperviscosity in Waldenström macroglobulinemia.

Abeykoon JP, Zanwar S, Ansell SM, Winters J, Gertz MA, King RL, Murray D, Habermann T, Dingli D, Muchtar E, Go RS, Leung N, Inwards DJ, Buadi FK, Dispenzieri A, Lacy MQ, Lin Y, Gonsalves WI, Kourelis T, Witzig TE, Thompson C, Vincent Rajkumar S, Kyle RA, Kumar S, Kapoor P.

Am J Hematol. 2018 Nov;93(11):1384-1393. doi: 10.1002/ajh.25254. Epub 2018 Oct 2.

PMID:
30121949
15.

Comparable outcomes using propylene glycol-free melphalan for autologous stem cell transplantation in multiple myeloma.

Miller KC, Gertz MA, Buadi FK, Hayman SR, Wolf RC, Lacy MQ, Dispenzieri AA, Dingli D, Kapoor P, Gonsalves WI, Kourelis T, Hogan WJ, Kumar SK.

Bone Marrow Transplant. 2018 Aug 16. doi: 10.1038/s41409-018-0302-6. [Epub ahead of print]

PMID:
30116014
16.

Acute hyperviscosity: syndromes and management.

Gertz MA.

Blood. 2018 Sep 27;132(13):1379-1385. doi: 10.1182/blood-2018-06-846816. Epub 2018 Aug 13. Review.

PMID:
30104220
17.

Plasma cell proliferative index post-transplant is a powerful predictor of prognosis in myeloma patients failing to achieve a complete response.

Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Muchtar E, Lust JA, Rajkumar VS, Gertz MA.

Bone Marrow Transplant. 2018 Aug 7. doi: 10.1038/s41409-018-0280-8. [Epub ahead of print]

PMID:
30087461
18.

Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma.

Kumar SK, Buadi FK, LaPlant B, Halvorson A, Leung N, Kapoor P, Dingli D, Gertz MA, Go RS, Bergsagel PL, Lin Y, Dispenzieri A, Hwa YL, Fonder A, Hobbs M, Fonseca R, Hayman SR, Stewart AK, Lust JA, Mikhael J, Gonsalves W, Reeder C, Skacel T, Rajkumar SV, Lacy MQ.

Blood Cancer J. 2018 Jul 30;8(8):70. doi: 10.1038/s41408-018-0106-3.

19.

Selecting Initial Therapy for Newly Diagnosed Waldenström Macroglobulinemia.

Gertz MA.

J Clin Oncol. 2018 Sep 20;36(27):2749-2751. doi: 10.1200/JCO.2018.79.3273. Epub 2018 Jul 27. No abstract available.

PMID:
30052482
20.

Immunoglobulin light chain amyloidosis: 2018 Update on diagnosis, prognosis, and treatment.

Gertz MA.

Am J Hematol. 2018 Sep;93(9):1169-1180. doi: 10.1002/ajh.25149.

PMID:
30040145
21.

Daratumumab for the treatment of AL amyloidosis.

Sidiqi MH, Gertz MA.

Leuk Lymphoma. 2018 Jul 22:1-7. doi: 10.1080/10428194.2018.1485914. [Epub ahead of print]

PMID:
30033840
22.

Serum free light chain measurements to reduce 24-h urine monitoring in patients with multiple myeloma with measurable urine monoclonal protein.

Tschautscher M, Rajkumar V, Dispenzieri A, Lacy M, Gertz M, Buadi F, Dingli D, Hwa L, Fonder A, Hobbs M, Hayman S, Zeldenrust S, Lust J, Russell S, Leung N, Kapoor P, Go R, Lin Y, Gonsalves W, Kourelis T, Warsame R, Kyle R, Kumar S.

Am J Hematol. 2018 Oct;93(10):1207-1210. doi: 10.1002/ajh.25215. Epub 2018 Aug 15.

PMID:
30016549
23.

Clinical characteristics and treatment outcomes in IgE multiple myeloma: A case-control study.

Jurczyszyn A, Castillo JJ, Vesole DH, Liu J, Avivi I, Waszczuk-Gajda A, Lech-Maranda E, Gentile M, Mikala G, Guerrero-Garcia T, Suska A, Gertz MA.

Am J Hematol. 2018 Sep;93(9):E238-E241. doi: 10.1002/ajh.25209. Epub 2018 Aug 6. No abstract available.

PMID:
29989240
24.

Utilization of hematopoietic stem cell transplantation for the treatment of multiple myeloma: a Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART) consensus statement.

Gonsalves WI, Buadi FK, Ailawadhi S, Bergsagel PL, Chanan Khan AA, Dingli D, Dispenzieri A, Fonseca R, Hayman SR, Kapoor P, Kourelis TV, Lacy MQ, Larsen JT, Muchtar E, Reeder CB, Sher T, Stewart AK, Warsame R, Go RS, Kyle RA, Leung N, Lin Y, Lust JA, Russell SJ, Zeldenrust SR, Fonder AL, Hwa YL, Hobbs MA, Mayo AA, Hogan WJ, Rajkumar SV, Kumar SK, Gertz MA, Roy V.

Bone Marrow Transplant. 2018 Jul 9. doi: 10.1038/s41409-018-0264-8. [Epub ahead of print] Review.

PMID:
29988062
25.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH 3rd, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T.

N Engl J Med. 2018 Jul 5;379(1):22-31. doi: 10.1056/NEJMoa1716793.

PMID:
29972757
26.

Prognostic Significance of Stringent Complete Response after Stem Cell Transplantation in Immunoglobulin Light Chain Amyloidosis.

Sidiqi MH, Aljama MA, Jevremovic D, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz MA.

Biol Blood Marrow Transplant. 2018 Jun 30. pii: S1083-8791(18)30366-5. doi: 10.1016/j.bbmt.2018.06.027. [Epub ahead of print]

PMID:
29964192
27.

Autologous Stem Cell Transplant for Immunoglobulin Light Chain Amyloidosis Patients Aged 70 to 75.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kapoor P, Kourelis TV, Hogan WJ, Kumar SK, Gertz MA.

Biol Blood Marrow Transplant. 2018 Jun 20. pii: S1083-8791(18)30329-X. doi: 10.1016/j.bbmt.2018.06.017. [Epub ahead of print]

PMID:
29933071
28.

Risk stratification of smoldering multiple myeloma incorporating revised IMWG diagnostic criteria.

Lakshman A, Rajkumar SV, Buadi FK, Binder M, Gertz MA, Lacy MQ, Dispenzieri A, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Blood Cancer J. 2018 Jun 12;8(6):59. doi: 10.1038/s41408-018-0077-4.

29.

Defining Lymphoplasmacytic Lymphoma: Does MYD88L265P Define a Pathologically Distinct Entity Among Patients With an IgM Paraprotein and Bone Marrow-Based Low-Grade B-Cell Lymphomas With Plasmacytic Differentiation?

Fang H, Kapoor P, Gonsalves WI, Frederick LA, Viswanatha D, Howard MT, He R, Morice WG 2nd, McPhail ED, Greipp PT, Ansell SM, Kyle RA, Gertz MA, Paludo J, Abeykoon J, King RL.

Am J Clin Pathol. 2018 Jul 3;150(2):168-176. doi: 10.1093/ajcp/aqy041.

PMID:
29868855
30.

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Higgins L, Nasr SH, Said SM, Kapoor P, Dingli D, King RL, Rajkumar SV, Kyle RA, Kourelis T, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Ansell SM, Gonsalves WI, Thompson CA, Fervenza FC, Zand L, Hwa YL, Jevremovic D, Shi M, Leung N.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1037-1046. doi: 10.2215/CJN.13041117. Epub 2018 May 30.

PMID:
29848505
31.

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018.

Gertz MA.

Blood Cancer J. 2018 May 23;8(5):44. doi: 10.1038/s41408-018-0080-9. Review.

32.

Independent Prognostic Value of Stroke Volume Index in Patients With Immunoglobulin Light Chain Amyloidosis.

Milani P, Dispenzieri A, Scott CG, Gertz MA, Perlini S, Mussinelli R, Lacy MQ, Buadi FK, Kumar S, Maurer MS, Merlini G, Hayman SR, Leung N, Dingli D, Klarich KW, Lust JA, Lin Y, Kapoor P, Go RS, Pellikka PA, Hwa YL, Zeldenrust SR, Kyle RA, Rajkumar SV, Grogan M.

Circ Cardiovasc Imaging. 2018 May;11(5):e006588. doi: 10.1161/CIRCIMAGING.117.006588.

PMID:
29752392
33.

Waldenström macroglobulinemia treatment algorithm 2018.

Gertz MA.

Blood Cancer J. 2018 May 1;8(4):40. doi: 10.1038/s41408-018-0076-5. Review.

34.

Impact of duration of induction therapy on survival in newly diagnosed multiple myeloma patients undergoing upfront autologous stem cell transplantation.

Chakraborty R, Muchtar E, Kumar SK, Buadi FK, Dingli D, Dispenzieri A, Hayman SR, Hogan WJ, Kapoor P, Lacy MQ, Leung N, Warsame R, Kourelis T, Gonsalves W, Gertz MA.

Br J Haematol. 2018 Jul;182(1):71-77. doi: 10.1111/bjh.15244. Epub 2018 Apr 29.

PMID:
29707759
35.

Plasma cell proliferative index predicts outcome in immunoglobulin light chain amyloidosis treated with stem cell transplantation.

Sidiqi MH, Aljama MA, Jevremovic D, Morice WG, Timm M, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Leung N, Hogan WJ, Gertz M.

Haematologica. 2018 Jul;103(7):1229-1234. doi: 10.3324/haematol.2018.189985. Epub 2018 Apr 19.

36.

Time to plateau as a predictor of survival in newly diagnosed multiple myeloma.

Mellors PW, Binder M, Buadi FK, Lacy MQ, Gertz MA, Dispenzieri A, Hayman SR, Kapoor P, Gonsalves WI, Hwa YL, Fonder A, Hobbs M, Kourelis T, Warsame R, Zeldenrust SR, Lust JA, Leung N, Go RS, Kyle RA, Vincent Rajkumar S, Kumar SK.

Am J Hematol. 2018 Jul;93(7):889-894. doi: 10.1002/ajh.25113.

PMID:
29659048
37.

Analysis of Clinical Factors and Outcomes Associated with Nonuse of Collected Peripheral Blood Stem Cells for Autologous Stem Cell Transplants in Transplant-Eligible Patients with Multiple Myeloma.

Kansagra A, Gonsalves WI, Gertz MA, Buadi FK, Dingli D, Dispenzieri A, Lacy MQ, Hayman SR, Kapoor P, Muchtar E, Kourelis TV, Warsame R, Leung N, Zeldenrust SR, Lust JA, Rajkumar SV, Kyle RA, Hogan W, Kumar SK.

Biol Blood Marrow Transplant. 2018 Apr 12. pii: S1083-8791(18)30188-5. doi: 10.1016/j.bbmt.2018.04.007. [Epub ahead of print]

PMID:
29656139
38.

Multiple myeloma - a cure within reach.

Gertz MA.

Leuk Lymphoma. 2018 Apr 4:1-3. doi: 10.1080/10428194.2018.1452221. [Epub ahead of print] No abstract available.

PMID:
29616849
39.

Light chain type predicts organ involvement and survival in AL amyloidosis patients receiving stem cell transplantation.

Sidiqi MH, Aljama MA, Muchtar E, Buadi FK, Warsame R, Lacy MQ, Dispenzieri A, Dingli D, Leung N, Gonsalves WI, Kumar SK, Kapoor P, Kourelis TV, Hogan WJ, Gertz MA.

Blood Adv. 2018 Apr 10;2(7):769-776. doi: 10.1182/bloodadvances.2018016782.

40.

Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemia.

Paludo J, Abeykoon JP, Shreders A, Ansell SM, Kumar S, Ailawadhi S, King RL, Koehler AB, Reeder CB, Buadi FK, Dispenzieri A, Lacy MQ, Dingli D, Witzig TE, Go RS, Gonsalves WI, Kourelis T, Warsame R, Leung N, Habermann TM, Hayman S, Lin Y, Kyle RA, Rajkumar SV, Gertz MA, Kapoor P.

Ann Hematol. 2018 Aug;97(8):1417-1425. doi: 10.1007/s00277-018-3311-z. Epub 2018 Apr 3.

PMID:
29610969
41.

Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria.

Muchtar E, Dispenzieri A, Leung N, Lacy MQ, Buadi FK, Dingli D, Grogan M, Hayman SR, Kapoor P, Hwa YL, Fonder A, Hobbs M, Chakraborty R, Gonsalves W, Kourelis TV, Warsame R, Russell S, Lust JA, Lin Y, Go RS, Zeldenrust S, Kyle RA, Rajkumar SV, Kumar SK, Gertz MA.

Leukemia. 2018 Oct;32(10):2240-2249. doi: 10.1038/s41375-018-0060-x. Epub 2018 Feb 20.

PMID:
29581546
42.

Prognostic significance of interphase FISH in monoclonal gammopathy of undetermined significance.

Lakshman A, Paul S, Rajkumar SV, Ketterling RP, Greipp PT, Dispenzieri A, Gertz MA, Buadi FK, Lacy MQ, Dingli D, Fonder AL, Hayman SR, Hobbs MA, Gonsalves WI, Hwa YL, Kapoor P, Leung N, Go RS, Lin Y, Kourelis TV, Warsame R, Lust JA, Russell SJ, Zeldenrust SR, Kyle RA, Kumar SK.

Leukemia. 2018 Aug;32(8):1811-1815. doi: 10.1038/s41375-018-0030-3. Epub 2018 Jan 30. No abstract available.

PMID:
29568092
43.

The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Rajkumar SV, Kumar SK.

Leukemia. 2018 May;32(5):1243-1246. doi: 10.1038/s41375-018-0022-3. Epub 2018 Jan 30. No abstract available.

PMID:
29568089
44.

Stem Cell Transplantation for Light Chain Amyloidosis: Decreased Early Mortality Over Time.

Sidiqi MH, Aljama MA, Buadi FK, Warsame RM, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ, Gertz MA.

J Clin Oncol. 2018 May 1;36(13):1323-1329. doi: 10.1200/JCO.2017.76.9554. Epub 2018 Mar 20.

PMID:
29558277
45.

Digoxin use in systemic light-chain (AL) amyloidosis: contra-indicated or cautious use?

Muchtar E, Gertz MA, Kumar SK, Lin G, Boilson B, Clavell A, Lacy MQ, Buadi FK, Hayman SR, Kapoor P, Dingli D, Rajkumar SV, Dispenzieri A, Grogan M.

Amyloid. 2018 Jun;25(2):86-92. doi: 10.1080/13506129.2018.1449744. Epub 2018 Mar 12.

PMID:
29529877
46.

Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis.

Sidana S, Tandon N, Dispenzieri A, Gertz MA, Dingli D, Jevremovic D, Morice WG, Kapoor P, Kourelis TV, Lacy MQ, Hayman SR, Buadi FK, Leung N, Go RS, Lin Y, Russell SJ, Lust JA, Zeldenrust SR, Warsame R, Hwa YL, Hobbs M, Fonder A, Kyle RA, Rajkumar SV, Kumar SK, Gonsalves WI.

Leukemia. 2018 Jun;32(6):1421-1426. doi: 10.1038/s41375-018-0063-7. Epub 2018 Feb 21.

47.

Fitting mSMART Into the Current Clinical Management of Waldenström Macroglobulinemia-Reply.

Kapoor P, Gertz MA, Ansell SM.

JAMA Oncol. 2018 May 1;4(5):745-746. doi: 10.1001/jamaoncol.2017.5100. No abstract available.

PMID:
29392293
48.

Testicular plasmacytoma: unique location or circumstantial presentation?

Muchtar E, Bladé J, Gertz MA.

Leuk Lymphoma. 2018 Aug;59(8):1769-1771. doi: 10.1080/10428194.2017.1421763. Epub 2018 Jan 9. No abstract available.

PMID:
29316841
49.

Reply to Castillo et al.

Abeykoon JP, King R, Ansell SM, Rajkumar SV, Paludo J, Kyle RA, Kumar S, Gertz MA, Kapoor P.

Am J Hematol. 2018 Mar;93(3):E71-E73. doi: 10.1002/ajh.25029. Epub 2018 Feb 5. No abstract available.

PMID:
29314230
50.

Safety Outcomes for Autologous Stem Cell Transplant in Multiple Myeloma.

Gertz MA, Buadi FK, Hayman SR, Lacy MQ, Dispenzieri A, Dingli D, Gonsalves WI, Kumar S, Kapoor P, Kourelis T, Hogan WJ.

Mayo Clin Proc. 2018 Jan;93(1):56-58. doi: 10.1016/j.mayocp.2017.09.012.

PMID:
29304921

Supplemental Content

Support Center